X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


最新的帖子

七月 10, 2019

Intended Use and Packaging Risks for Compounding Pharmacies (503Bs)

In 2015, the FDA shed light on a problematic practice within the healthcare industry involving improper, off-label use of syringes as closed container storage systems for compounded or repackaged drugs. The incidents cited revealed that interaction with rubber plungers in syringes that were not cleared for the purpose of closed container storage resulted in the loss of potency of several drugs when administration was delayed.<sup>1</sup>
Amy Kim

Amy Kim

Sr. Specialist, Scientific Communications, SA & TS

以前的博客
Elastomers

六月 25, 2019

Bromobutyl versus Chlorobutyl Rubber Formulations - General Aspects

Heike Kofler

Dr. Heike Kofler

Manager, Technical Customer Support Europe

CPhI China Tradeshow

六月 20, 2019

West Helps Simplify the Journey™ in China

Jessie Zhang

Jessie Zhang

Manager, Global Communications, AP

Stoppers and Plungers

五月 31, 2019

Stability Studies of Pharmaceutical Packaging Materials in China

Lynn Yao

Lynn Yao

Manager, Scientific Affairs, AP

Integrated Solutions Program

五月 16, 2019

Delivering Macromolecules: Challenges Associated with the Delivery of Biologic Drugs

Victoria Morgan

Victoria Morgan

Director, Segment Marketing, Biologics

Introducing Integrated Solutions

五月 02, 2019

FDA Guidance Affecting cGMP Compounding Pharmacies (503Bs)

Amy Kim

Amy Kim

Sr. Specialist, Scientific Communications, SA & TS

Load more